Pfizer Inc.

04/27/2026 | Press release | Distributed by Public on 04/27/2026 15:17

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders
(a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 23, 2026.
(b) Shareholders voted on the matters set forth below.
1. The nominees for election to the Company's Board of Directors set forth in Item 1 to the Company's Proxy Statement filed with the U.S. Securities and Exchange Commission on March 12, 2026 were elected to hold office until the Company's next Annual Meeting of Shareholders, based upon the following votes:
Nominee
Votes For
Votes Against
Abstentions
Broker non-vote
Ronald E. Blaylock 3,442,653,662 102,600,748 11,374,500 941,392,137
Albert Bourla 3,261,211,737 272,132,573 23,284,563 941,392,137
Mortimer J. Buckley 3,403,974,675 141,036,932 11,617,303 941,392,137
Susan Desmond-Hellmann 3,401,932,807 141,056,147 13,639,956 941,392,137
Joseph J. Echevarria 2,929,511,380 612,413,502 14,702,274 941,392,137
Scott Gottlieb 3,415,886,776 130,394,185 10,343,738 941,392,137
Dan R. Littman 3,383,769,589 161,740,872 11,118,449 941,392,137
Shantanu Narayen 3,313,318,763 231,613,932 11,695,915 941,392,137
Suzanne Nora Johnson 3,272,936,863 273,506,151 10,185,896 941,392,137
James Quincey 3,453,778,741 91,549,236 11,300,933 941,392,137
James C. Smith 3,284,035,682 261,217,699 11,375,529 941,392,137
Cyrus Taraporevala 3,468,177,423 76,665,721 11,785,766 941,392,137
2. The proposal to ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the 2026 fiscal year was approved based upon the following votes:
Votes for approval
4,160,827,231
Votes against
321,979,096
Abstentions
15,214,720
Broker non-votes
n/a
3. The proposal to approve the Pfizer Inc. 2019 Stock Plan, as amended April 2026 was approved based upon the following votes:
Votes for approval
3,227,692,578
Votes against
305,428,376
Abstentions
23,507,956
Broker non-votes
941,392,137
4. The proposal to approve, on an advisory basis, the 2026 compensation of the Company's Named Executive Officers was approved based upon the following votes:
Votes for approval
3,099,249,442
Votes against
423,935,881
Abstentions
33,443,287
Broker non-votes
941,392,137
5. The shareholder proposal to Adopt Adopt An Independent Chair Policy was not approved based upon the following votes:
Votes for approval
1,015,206,372
Votes against
2,509,042,021
Abstentions
32,354,566
Broker non-votes
941,392,137
Pfizer Inc. published this content on April 27, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 27, 2026 at 21:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]